UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
_____________

FORM 8-K
_____________

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
 
Date of report (Date of earliest event reported): April 4, 2008
 
Keryx Biopharmaceuticals, Inc.
(Exact Name of Registrant as Specified in Charter)
 
Delaware
(State or Other Jurisdiction
of Incorporation)
000-30929
(Commission File Number)
13-4087132
(IRS Employer Identification No.)
 
750 Lexington Avenue
New York, New York 10022
(Address of Principal Executive Offices)

(212) 531-5965
(Registrant's telephone number, including area code)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

£  
Written communications pursuant to Rule 425 under the Securities Act.
   
£  
Soliciting material pursuant to Rule 14a-12 under the Exchange Act.
   
£  
Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act.
   
£  
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
 
 
 Item 8.01.  Other Events.

On April 4, 2008, Keryx Biopharmaceuticals, Inc. (the “Company”) issued a press release announcing that it is implementing a strategic restructuring plan to reduce its cash burn rate and re-focus its development efforts. A copy of this press release is being filed as Exhibit 99.1 to this report and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

The following exhibit is filed as a part of this report:
 
Exhibit
Number
   Description
     
99.1    
   Press Release dated April 4, 2008.
 

SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
     
 
Keryx Biopharmaceuticals, Inc.
(Registrant)
   
   
 Date: April 4, 2008  
 
 		  
 		  
 
  By:
   /s/ Beth F. Levine
 
Beth F. Levine
Senior Vice President, Chief Compliance
Officer, General Counsel and Secretary
 

INDEX TO EXHIBITS
 
Exhibit
Number
   Description
     
99.1
   Press Release dated April 4, 2008.